Lyell Immunopharma (LYEL) EBT Margin Growth (3y) (2023 - 2026)

Lyell Immunopharma (LYEL) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,237.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -408.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Lyell Immunopharma 298.14 Mn 298.14 Mn - -503.26 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -503.26 Mn
Dec 31, 2025 -241.12 Mn
Sep 30, 2025 559.81 Mn
Jun 30, 2025 -144.30 Mn
Mar 31, 2025 -180.95 Mn
Dec 31, 2024 -509.43 Mn
Sep 30, 2024 -36.37 Mn
Jun 30, 2024 -98.94 Mn
Mar 31, 2024 -249.47 Mn
Dec 31, 2023 -235.40 Mn
Sep 30, 2023 -27.67 Mn
Jun 30, 2023 -33.30 Mn